Clinuvel Pharmaceuticals is a publicly listed company. The company’s stock can be purchased through two different listing or via an ADR program in the US. Clinuvel does not issue stock directly to investors.
The company’s primary listing is with the Australian Securities Exchange (ASX) under the ticker code CUV. The ASX maintains an extensive education program on its website to help potential investors understand the stock market and ASX listed companies. For more information, log onto the ASX Education website.
Clinuvel’s ASX register is maintained by Computershare. Through the Computershare website, CUV holders can view their account balances and view and change their account details and communications preferences.
Clinuvel maintains a secondary listing with the Frankfurt Xetra-Dax with the ticker code UR9.
Clinuvel shares can be purchased in the US through the Bank of NY Mellon’s Level 1 American Depository Receipt (ADR) program under the ticket code CLVLY. For more information on ADRs, log onto the Bank of NY Mellon’s ADR investors website. Following the consolidation of the ASX listed CUV, CLVLY is now at a ratio of 1 ADR: 1 Ordinary Share of CUV. For more information, see this announcement from the Bank of NY Mellon.
Please contact a financial advisor for more investing information.